| Description: |
SB-431542 is a novel small molecule inhibitor of the type I TGF-beta receptor, on a panel of human malignant glioma cell lines. SB-431542 blocked the phosphorylation and nuclear translocation of the SMADs, intracellular mediators of TGF-beta signaling, with decreased TGF-beta-mediated transcription. Furthermore, SB-431542 inhibited the expression of two critical effectors of TGF-beta-vascular endothelial growth factor and plasminogen activator inhibitor-1. SB-431542 treatment of glioma cultures inhibited proliferation, TGF-beta-mediated morphologic changes, and cellular motility. Together, our results suggest that small molecule inhibitors of TGF-beta receptors may offer a novel therapy For malignant gliomas by reducing cell proliferation, angiogenesis, and motility.For the detailed information of SB-431542, the solubility of SB-431542 in water, the solubility of SB-431542 in DMSO, the solubility of SB-431542 in PBS buffer, the animal experiment (test) of SB-431542, the cell expriment (test) of SB-431542, the in vivo, in vitro and clinical trial test of SB-431542, the EC50, IC50,and Affinity of SB-431542, Please contact DC Chemicals. |
